.: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies."
.

.
boston cio of the year® orbie® awards
.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
.
advertisement
.